Jörgen Vrenning is retiring as CFO of NeoDynamics
NeoDynamics AB (Spotlight Stockholm: NEOD), today announce that CFO and former CEO Jörgen Vrenning, has decided to leave the company after eight years of employment. Jörgen will continue in an advisory role until end of May 2021, in order to ensure a smooth transition. Anna Eriksrud, CEO NeoDynamics assumes the role as Interim CFO.
“It has been a very exciting time at NeoDynamics, from the start of the NeoNavia project eight years ago. I have had a plan for a long time not to work operationally when I turn 63. I now look forward to having more time with my family, but I am also open to board assignments. I am proud to have been a part of NeoDynamics and I will miss all my fantastic colleagues”, says Jörgen.
“I would like to thank Jörgen for his great contribution over the years and we wish him good luck in the future”, says Anna Eriksrud.
For additional information please contact:
Anna Eriksrud, CEO NeoDynamics AB (publ).
Phone +46 70 844 49 66, e-mail: anna.eriksrud@neodynamics.com
This information is such information that NeoDynamics AB (publ) is obliged to publish in accordance with the EU Market Abuse Regulation. The information was submitted, through the care of the above contact person, for publication on November 2, 2020, at 12.20 CET.
About NeoDynamics AB (publ)
NeoDynamics AB (publ) is a Swedish Medical Technology company dedicated to advancing diagnosis and care of breast cancer. The Company has an innovative biopsy system, NeoNavia, built on patented micro pulse technology, which is based on research from Karolinska Institutet in Sweden. The system is designed so that both patients and doctors will receive an accurate lesion targeting and high tissue yields for correct diagnosis and individualized treatment. Leading clinics in UK, Germany, and Sweden are evaluating NeoNavia, and a commercial launch is expected during 2020.
About NeoNavia
NeoNavia is the tradename of the biopsy system, intended and used for ultrasound guided sampling. NeoNavia consists of a base unit, a handheld driver, and three types of biopsy needles. micro pulse technology drives each needle, enabling a simpler needle-insertion and increasing precision in the suspected lesion. The system is designed so that both patients and doctors will receive an accurate lesion targeting and high tissue yields for correct diagnosis and individualized treatment.
About the micro pulse technology
The patented micro pulse technology is based on pneumatic mechanisms, which enable high precision and positioning of the biopsy needle, regardless of issue-type. The handheld driver consists of a drive-unit which generates pulsation. With power from the base unit, the handheld driver accelerates the biopsy needle with great control even when the distances are small. This allows a distinct, stepwise needle insertion without affecting the nearby tissue. In turn, this creates good access and flexibility in areas where tissue sampling of lesions is considered problematic.